The prognosis of acute myeloid leukaemia has recently improved through the application of intensive chemotherapy and bone marrow transplantation. However, intensive chemotherapy is not used in elderly patients or in patients with hypoplastic leukaemia or myelodysplastic syndrome because of severe complications. The incidence of induction death among elderly patients in their initial induction therapy, even when supported with cytokines, is higher than 10% (Schiffer, 1996) . Indications for bone marrow transplantation are limited to young patients with HLA-matched donors (Goldman, 1994 ). Differentiation therapy is one possible approach for surviving patients who cannot be treated with intensive chemotherapy or bone marrow transplantation.
Differentiation therapy has been used successfully to treat acute promyelocytic leukaemia (Degos et al, 1995) . All-trans retinoic acid induces complete remission in more than 90% of patients with acute promyelocytic leukaemia with a t (15; 17) chromosomal translocation. However, the use of all-trans retinoic acid is limited to acute promyelocytic leukaemia. Vitamin D is another potential inducer for differentiation therapy. The active form of vitamin D, la,25-dihydroxyvitamin D3 (1,25(OH)2D3), induces differentiation in mouse and in human leukaemia cells Miyaura et al, 1981) and prolongs the survival of mice inoculated with myeloid leukaemia cells (Honma et al, 1983) . However, clinical trials of 1,25(OH)2D3 in patients with myelodysplastic syndrome have not been successful because of hypercalcaemia (Koeffler et al, 1985) . Several analogues of 1,25(OH)2D3 that show anti-cancer activity and only weak activity for inducing hypercalcaemia have been developed, but they are not yet available for the clinical treatment of cancer or leukaemia (Abe et al, 1991; Pakkala et al, 1995) . To overcome the adverse effects of vitamin D, we are investigating the effects of the combination of 1,25(OH)2D3 with other drugs . As the combination of all-trans retinoic acid with low doses of anti-cancer drugs produced better results than either drug alone for the treatment of acute myeloid leukaemia (Venditti et al, 1995) , in this study, we investigated the effects of the combination of 1,25(OH)2D3 and its analogues with various anti-cancer drugs on growth inhibition and differentiation induction in myelomonocytic leukaemia cells.
MATERIALS AND METHODS Materials la,25-Dihydroxyvitamin D7 (1,25(OH)2D7), 24-epi-lac,25-dihydroxyvitamin D2 (24-epi-1,25(OH)2D2), 1 a-hydroxyvitamin D3
(1 a(OH)D3), 1 a(OH)D2, 1 a(OH)D4 and la(OH)D7 were synthesized (Figure 1 ) (Tachibana and Tsuji, 1992) Cell lines and cell culture Human myeloid leukaemia U937, HL-60, ML-1, THP-1, P39/TSU, P31/FUJ and NB4 cells (Lanotte et al, 1991) were cultured in suspension in RPMI 1640 medium containing 10% fetal bovine serum and 80 gg ml gentamicin at 37°C in a humidified atmosphere of 5% carbon dioxide in air .
Cell growth and differentiation Suspensions of cells were cultured with or without the test compounds in multidishes. The cells were counted in a Model ZM Coulter Counter (Coulter Electronics, Luton, UK). Nitroblue tetrazolium (NBT) reduction was assayed colorimetrically . Lysozyme activity in the conditioned medium was determined using a lysoplate . One unit is equivalent to 1 ,ug ml-1 egg-white lysozyme. Cell morphology was examined in cell smears stained with May-Gruinwald and Giemsa solutions (Merck, Darmstadt, Germany).
Analysis of the effects of combinations of drugs
The interaction of the two compounds was quantified by determining the combination index (CI) according to the classic isobologram equation:
where Dx is the concentration of one drug alone required to produce an effect and Di and D2 are the doses of compounds l and 2, respectively, in combination that produce the same effect (Berenbaum, 1989) . Using this analysis, the combined effects of the two drugs can be assessed as being either additive (CI = 1), synergistic (CI < 1) or antagonistic (CI > 1). An isobologram was also used to determine the effect of combinations of drugs (Berenbaum, 1989) . Concentration-dependent effects were determined from isoeffective concentrations for each compound and for one compound with fixed concentrations of another. The additive lines were indicated as calculated by mode I and mode II systems (Steel and Peckham, 1979) .
Flow cytometry
Expression of the granulocyte-and monocyte-specific antigens CDllb and CD14 on the cell surface was determined using indirect immunofluorescent staining and flow cytometry . Mouse monoclonal antibodies to CDl1b (2LPM19c), CD14 (TUK4), control mouse IgGI, IgG2a and FITC-conjugated F(ab )2 fragment of goat antimouse IgG were obtained from Dako (Glostrup, Denmark). The stained cells were assayed using a flow cytometer (Epics XL; Coulter Electronics) (1998) (Steel and Peckham, 1979 (Overton, 1988 We examined the effects of anti-cancer drugs in combination with 1,25(OH)2D3 on NBT-reducing activity, a typical marker of myelomonocytic differentiation, in U937 cells. The anti-cancer drugs showed only weak activity for inducing NBT reduction (Table 1) . Next, the NBT-reducing activity induced by anti-cancer drugs in combination with 3 x 10-9 M 1,25(OH)2D3 was examined. HU plus 1,25(OH)2D3 effectively increased the activity 6.2-fold from HU alone and 5.5-fold from 1,25(OH)2D3 alone (Table 1) . Camptothecin and Ara-C in combination with 1,25(OH)2D3 modestly induced this activity. Among the anti-cancer drugs we examined, HU had the greatest synergistic effect with 1,25(OH)2D3 for growth inhibition and induction of NBT-reducing activity in U937 cells. Figure 3A and B) . HU alone induced NBT-reducing activity in monoblastic THP-1 cells but not in other monoblastic P39/TSU or P3 1/FUJ cells. It also effectively enhanced the differentiation of these cells induced by 1,25(OH)2D3 (Figure 3C-E) . NB4 cells are promyelocytic leukaemia cells with a t(15; 17) chromosomal translocation and have been reported to be resistant to 1,25(OH)2D3 (Testa et al, 1994) . HU also induced the NBTreducing activity in NB4 cells in combination with 1,25(OH)2D3 ( Figure 3F ). Thus, HU plus 1,25(OH)2D3 effectively induces the differentiation of myelomonocytic leukaemia cells.
Effects of HU in combination with vitamin D derivatives on growth inhibition and differentiation induction in U937 cells 24-Epi-1,25(OH)2D2 and 1,25(OH)2D7 have been reported to exhibit less hypercalcaemic activity than 1,25(OH)2D3 and to be able to induce the differentiation of HL-60 cells (Sato et al, 1991) . They also induced the NBT-reducing activity of U937 cells, and HU effectively enhanced the activities induced by their suboptimal concentrations ( Figure 4A ). 24-Epi-1,25(OH)2D2 and 1,25-(OH)2D7 inhibited the proliferation of U937 cells concentration dependently, with IC50 values of 2.25 x 10-7 M and 2.28 x 10-7 M respectively (data not shown). At a low concentration of 9 x 10-9 M, they slightly inhibited the proliferation of U937 cells and augmented the growth inhibition in combination with 50 gM HU ( Table 2) .
We have previously reported that Ia(OH)D3 induces the differentiation of monoblastic leukaemia cells as well as 1,25(OH)2D3 and is less toxic than 1,25(OH)2D3 (Honma et al, 1983; Okabe-Kado et al, 1992) . We examined the effects of several lac(OH)D derivatives on British Journal of Cancer (1998) 77(1) Differentiation by la-hydroxyvitamin D plus hydroxyurea 37 growth inhibition and differentiation induction in U937 cells in combination with HU. la(OH)D3 inhibited proliferation with an IC50 value of 0.67 x 10-7 M and induced myelomonocytic differentiation markers, such as the NBT-reducing and lysozyme activities of U937 cells ( Figure 4B , data not shown). HU effectively enhanced the NBT-reducing activity in U937 cells induced by la(OH)D3 ( Figure   4B ). For example, 1.2 x 10-8 M la(OH)D3 plus 50 gM HU induced this activity to 9.02 A560' while this activity was 8.54 A560 with 1.2 x 1o-6 M la(OH)D3 alone, indicating that lIt(OH)D3 was more than 100 times as active in the presence of HU. la(OH)D3 at 3 x 10-8 M slightly inhibited the proliferation of U937 cells, but augmented the inhibition in combination with HU (Table 2) . la(OH)D2, 1 x(OH)D4 A *.
and la(OH)D7 also inhibited the proliferation with IC50 values of 1.35 x 10-7, 1.47 x 10-7 and 3.25 x 10-7 M, respectively (data not shown), and induced the differentiation of monoblastic U937 ( Figure  4C) induced NBT-reducing activity of U937 cells from 0.83 A560 to 5.80, 5.50, 6.08 and 5.84 A560' respectively, and lysozyme activity from 1.99 units to 5.03, 5.11, 6.34 and 6.03 units, respectively (data not shown), indicating that la(OH)D4 was slightly more effective for inducing these activities than the others. The NBT-reducing activity induced by these la(OH)D derivatives in U937 cells was also effectively enhanced by HU ( Figure 4C ). HU enhanced the induction of NBT reduction by la(OH)D4 slightly more effectively than that by la(OH)D2 and l1z(OH)D7. At a concentration of 6 x 10-8 M, la(OH)D2 and la(OH)D4 inhibited the proliferation of U937 cells only slightly, while lIc(OH)D7 had no such effect, but they augmented the growth-inhibitory activity with HU (Table 2) . Thus, the combination of HU with la(OH)D derivatives is effective for inhibiting the proliferation and inducing the differentiation of U937 cells.
DISCUSSION
Among the anti-cancer drugs we examined, HU showed the greatest synergistic effect with 1,25(OH)2D3 with regard to growth inhibition and differentiation induction in U937 cells. Ara-C and camptothecin showed modest synergism with regard to growth inhibition, and Ara-C 1,25(OH)2D3 increased the cytotoxicity of Ara-C and HU against HL-60 cells (Studzinski et al, 1986) . HU inhibits nucleotide metabolism by inhibiting ribonucleotide reductase and Ara-C also inhibits nucleotide synthesis (Calabresi and Chabner, 1996) . HU enhances the differentiation of HL-60 cells induced by all-trans retinoic acid (Yen et al, 1987) . Ara-C induces the differentiation of some myeloid leukaemia cells and low doses of Ara-C have been used to treat acute myeloid leukaemia (Housset et al, 1982) . Other inhibitors of nucleotide metabolism also induce the differentiation of myeloid leukaemia cells (Bodner et al, 1981; Ishiguro and Sartorelli, 1985) . These findings indicate that some inhibitors of nucleotide metabolism may induce leukaemia cells to differentiate and to enhance differentiation induced by other compounds more effectively than other types of anti-cancer drugs. HU is useful for treating chronic myelogenous leukaemia and, when administered orally at daily doses from 500 to 3000 mg, for controlling blood cell counts within desirable ranges (Athens, 1993) . Its major adverse effect is bone marrow suppression, but the bone marrow recovers promptly if the drug is discontinued for a few days. Thus, HU can be used safely in elderly patients. Pharmacokinetic studies have shown that serum concentrations of HU after a single oral administration of 1000 mg reach 20-30 gg ml-' (263-394 gM) in 1-3 h, then gradually decrease and remain higher than 5 ,tg ml-' (66 ltM) for at least 10 h (Davidson and Winter, 1963; Bolton et al, 1965) . These findings indicate that the concentrations of HU needed to enhance the anti-leukaemic activity of vitamin D derivatives can be achieved clinically.
In this study, we observed the differentiation-inducing activities of lox(OH)D derivatives. After the administration of Ix(OH)D3, it is converted to an active form, 1,25(OH)2D3, by liver 25-hydroxylase (Holick et al, 1975) . ho(OH)D3 was more potent than 1,25(OH),D3 in increasing the survival time of mice inoculated with mouse myeloid leukaemia Ml cells (Honma et al, 1983) . The relatively stable concentrations of 1,25(OH),D3 after the administration of lIc(OH)D3 compared with 1,25(OH)2D3 may contribute to the advantage offered by lot(OH)D3. Interestingly, lIx(OH)D3 induced the differentiation of monoblastic leukaemia cells in vitro and was converted to 1,25(OH)2D3 in the cells (Okabe-Kado et al, 1992) . As monocytes also have 24-hydroxylase activity (Kamimura et al, 1995) and lac, 24-dihydroxyvitamin D3 can induce the differentiation of HL-60 cells to a similar extent as 1,25(OH)2D3 (Tanaka et al, 1982) , Ix(OH)D3 may act by being converted to 1,25(OH)2D3 and Ia, 24-dihydroxyvitamin D3 in monocytic cells. Thus, 1 x(OH)D3 affects leukaemia cells with monocytic characteristics both directly and indirectly. Acute monocytic leukaemia is more resistant to intensive chemotherapy than other types of acute myeloid leukaemia and its prognosis is poor (Fenaux et al, 1990) (Sjoden et al, 1985) . A clinical study in post-menopausal osteopenic patients showed that loc(OH)D2 at daily doses of less than 5.0,ug did not induce hypercalcaemia, whereas Ixc(OH)D3 at daily doses above 1.0 gg had toxic effects (Gallagher et al, 1994 ). An active form of lc-(OR)D7, 1,25(OH)2D7, has less hypercalcaemic activity (Sato et al, 1991) . Therefore, the 1 x(OH)D derivatives may be useful for treating monocytic leukaemia. Pharmacokinetics for serum concentrations of 1 cx(OH)D derivatives and their metabolites after administration should be further investigated. HU also effectively enhanced the differentiation induced by the I ax(OH)D derivatives. The combination of la(OH)D derivatives with HU may be a promising candidate for 'chemo-differentiation therapy' of acute monocytic leukaemia.
